Open access · CC-BY
via OpenAlex
Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance
Nina Rembiałkowska, Zofia Kocik, Amelia Kłosińska, Maja Kübler, Agata Pałkiewicz, Weronika Rozmus, Mikołaj Sędzik, Helena Wojciechowska, Agnieszka Gajewska-Naryniecka
Pharmaceuticals · 2025 · ▲ 45 citations
Genomic instability
Mitochondrial dysfunction
Altered intercellular communication
Chronic inflammation
Human
Abstract
Chronic inflammation, while originally a protective physiological response, is increasingly recognized as a key contributor to carcinogenesis. Prolonged inflammatory signaling leads to the sustained production of reactive oxygen and nitrogen species (ROS/RNS), resulting in direct and indirect DNA damage, including base modifications, strand breaks, and DNA cross-linking. Simultaneously, pro-inflammatory mediators such as NF-κB, IL-6, and TNF-α can interfere with DNA repair mechanisms, altering the efficiency of key pathways such as base excision and mismatch repair. Immune cells infiltrating chronically inflamed tissues, including macrophages and neutrophils, further exacerbate genomic instability through ROS/RNS release and cytokine production, creating a tumor-promoting microenvironment. Additionally, chronic inflammation has been implicated in the development of resistance to chemotherapy and radiotherapy by modulating DNA damage response pathways. Understanding the interplay between inflammation, genomic instability, and therapy resistance provides a framework for novel treatment strategies. Targeting chronic inflammation with non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or biological agents such as monoclonal antibodies offers promising avenues for cancer prevention and treatment. Targeting inflammation with NSAIDs, corticosteroids, and monoclonal antibodies shows promise in cancer prevention and therapy, particularly in lung and pancreatic cancer. These agents act by blocking key inflammatory pathways like COX-2, NF-κB, and cytokine signaling. However, potential adverse effects require further clinical evaluation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/ph18091406
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Rembiałkowska, N., Kocik, Z., Kłosińska, A., Kübler, M., Pałkiewicz, A., Rozmus, W., Sędzik, M., Wojciechowska, H., & Gajewska-Naryniecka, A. (2025). Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance. <em>Pharmaceuticals</em>. https://doi.org/10.3390/ph18091406
Vancouver
Rembiałkowska N, Kocik Z, Kłosińska A, Kübler M, Pałkiewicz A, Rozmus W, et al. Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance. Pharmaceuticals. 2025. doi:10.3390/ph18091406.
BibTeX
@article{nina2025Inflam,
title = {Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance},
author = {Nina Rembiałkowska and Zofia Kocik and Amelia Kłosińska and Maja Kübler and Agata Pałkiewicz and Weronika Rozmus and Mikołaj Sędzik and Helena Wojciechowska and Agnieszka Gajewska-Naryniecka},
journal = {Pharmaceuticals},
year = {2025},
doi = {10.3390/ph18091406},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Oxidative Medicine and Cellular Longevity 2013
Open access · CC-BY
DNA Damage in Inflammation-Related Carcinogenesis and Cancer Stem Cells
Respiratory Research 2018
Open access · OA
Idiopathic pulmonary fibrosis: pathogenesis and management
Frontiers in Pharmacology 2021
Open access · CC-BY
Cystic Fibrosis Lung Disease in the Aging Population
Frontiers in Cardiovascular Medicine 2026
Open access · CC-BY
The role of IL-6 in atherosclerosis: a narrative review
Frontiers in Genetics 2020
Open access · CC-BY
DNA-PKcs: A Multi-Faceted Player in DNA Damage Response
International Journal of Molecular Sciences 2023
Open access · CC-BY